Camargo Pharmaceutical Services has received a significant growth investment from a private non-institutional investment firm. This partnership will enable Camargo to take a long-term, disciplined approach to expand and develop new capabilities, drive growth in the accelerating 505(b)(2) market, and facilitate an increased global presence in drug development consulting. The Investor was attracted to Camargo's position as the market leader in this rapidly growing drug development consulting space, the Company's growth prospects, and the alignment with the management team.
"With this investment, Camargo is well positioned to meet our increasing client demand," says Ken Phelps, Chief Executive Officer of Camargo Pharmaceutical Services. "We are gratified that our partner has shown confidence in the market, our strategy, and capabilities. We look forward to the many opportunities ahead of us."
Camargo has worked extensively with every therapeutic division of the US Food and Drug Administration, enabling the Company to provide clients with the most cost- and time-effective strategies to navigate the regulatory pathway. As a highly experienced expert in drug and combination device product development, Camargo looks beyond regulatory approval to drive commercial success for its client-partners' products.
ArkMalibu, LLC served as exclusive financial advisor to Camargo, and Squire Patton Boggs, LLP and Alvarez & Marsal Taxand LLC provided legal and tax counsel, respectively.